GA
PRAH

Geneva Advisors’s PRA Health Sciences, Inc. PRAH Stock Holding History

Geneva Advisors’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,947
Closed -$649K – 806
2017
Q1 		$649K Buy
+9,947
New +$586K 0.01% 438

Other funds holding PRAH

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Geneva Advisors's PRAH Position: Q2 2017 in Review

Geneva Advisors sold out of PRA Health Sciences, Inc. (PRAH) in Q2 2017, closing a stake of 9,947 shares — an estimated $649K sold.

Geneva Advisors first reported a position in PRAH in Q1 2017 and held it in 1 quarter. The position peaked at $649K in Q1 2017. 236 funds tracked by Wall St. Rank hold PRAH as of Q2 2017.

  • Geneva Advisors reported no remaining PRA Health Sciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Geneva Advisors sold 9,947 PRA Health Sciences, Inc. shares in Q2 2017, an estimated $649K.
  • Geneva Advisors first reported a position in PRA Health Sciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Geneva Advisors's PRA Health Sciences, Inc. position peaked at $649K in Q1 2017.
  • 236 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.